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Flt3 ligand (Flt3L) is a nonredundant cytokine in type I interferon–producing cell (IPC) 
and dendritic cell (DC) development, and IPC and DC differentiation potential is confi  ned to 
Flt3+ hematopoietic progenitor cells. Here, we show that overexpression of human Flt3 
in Flt3− (Flt3−Lin−IL-7R𝗂−Thy1.1−c-Kit+) and Flt3+ (Flt3+Lin−IL-7R𝗂−Thy1.1−c-Kit+) 
hematopoietic progenitors rescues and enhances their IPC and DC differentiation potential, 
respectively. In defi  ned hematopoietic cell populations, such as Flt3− megakaryocyte/
erythrocyte-restricted progenitors (MEPs), enforced Flt3 signaling induces transcription of 
IPC, DC, and granulocyte/macrophage (GM) development–affi  liated genes, including STAT3, 
PU.1, and G-/M-/GM-CSFR, and activates differentiation capacities to these lineages. 
Moreover, ectopic expression of Flt3 downstream transcription factors STAT3 or PU.1 in 
Flt3− MEPs evokes Flt3 receptor expression and instructs differentiation into IPCs, DCs, and 
myelomonocytic cells, whereas GATA-1 expression and consecutive megakaryocyte/ 
erythrocyte development is suppressed. Based on these data, we propose a demand-
  regulated, cytokine-driven DC and IPC regeneration model, in which high Flt3L levels 
initiate a self-sustaining, Flt3-STAT3– and Flt3-PU.1–mediated IPC and DC differentiation 
program in Flt3+ hematopoietic progenitor cells.
Diff   erentiation of hematopoietic stem cells 
(HSCs) to mature hematopoietic cells is char-
acterized by progressive loss of developmental 
options and restriction to one lineage (1). In 
both mice and men, HSCs as well as multiple 
developmental intermediates with limited cel-
lular expansion and restriction to specifi  c ma-
ture cell types have been identifi  ed. These in-
clude myeloid progenitors, as clonal common 
myeloid progenitors (CMPs) that give rise to 
either granulocyte/macrophage progenitors 
(GMPs) or megakaryocyte/erythrocyte pro-
genitors (MEPs; references 2 and 3), and clonal 
common lymphoid progenitors (CLPs; refer-
ences 4 and 5), which robustly produce the 
  respective mature cell types. Hematopoietic 
diff  erentiation is regarded as a multi-linear, 
unidirectional process, and regeneration and 
expansion of specifi  c lineages are largely regu-
lated extrinsically by diff  erent hematopoietic 
cytokines. However, it is unclear whether un-
der physiologic conditions cytokines are capa-
ble to instruct HSCs and subsequent progenitors 
to diff  erentiate to lineage-restricted progenitors 
(extrinsic lineage determination). Alternatively, 
HSCs and subsequent progenitors commit to 
lineage-restricted progenitors by intrinsic dif-
ferentiation programs (intrinsic lineage deter-
mination), and restricted progenitors are con  -
secutively stimulated by hematopoietic cytokines 
produced upon demand (6, 7).
On the molecular level, access to lineage 
  developmental options and readiness to receive 
lineage-permissive and -instructive signals might 
be determined by graded, relative expression 
levels of diverse transcription factors and cyto-
kine receptors (8, 9). Indeed, it has been demon-
strated that genetic deletion or overexpression 
of diff  erent single transcription factors is suffi   -
cient to reprogram committed progenitors or 
mature cells to alternative hematopoietic  lineages 
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(10): Pax5-defi  cient pre–B cells lose B cell diff  erentiation po-
tential and mature into T and myelomonocytic cells, but re-
expression of Pax5 restores B cell commitment (11, 12); ectopic 
expression of GATA-1 instructs HSCs and CMPs and converts 
CLPs and GMPs to the megakaryocyte/erythrocyte lineage, 
respectively (13); and enforced expression of C/EBPα and 
C/EBPβ in B cells leads to macrophage diff  erentiation (14). 
Furthermore, it has been shown that artifi  cial expression of 
GM-CSF receptor and stimulation with the cognate ligand re-
direct CLPs and early T cell progenitors to myeloid lineage 
outcomes (15–17). This proves that hematopoietic lineage in-
struction can be mediated extrinsically by cytokines, at least in 
these   experimental settings.
DCs are important regulators of innate and adaptive im-
mune responses and are involved in initiation of immunity as 
well as in maintenance of self-tolerance (18–20). DCs are cells 
of the hematopoietic system and are continuously replenished 
from hematopoietic stem and progenitor cells (1). In mice, 
multiple DC subsets that diff  er in maturation state, pheno-
type, location, and in some functions were identifi  ed (21). 
Here, for simplicity, these will grossly be divided into 
CD11c+B220+ natural type I interferon–producing cells 
(IPCs; also called plasmacytoid cells or plasmacytoid pre-
DCs) and CD11c+B220− “  conventional” DCs, consisting of 
CD11c+CD8α−CD4−CD11b+,  CD11c+CD8α−CD4+CD11b+, 
and CD11c+CD8α+CD4−CD11b− subpopulations (21). 
  Although it was suggested that IPCs as well as conventional 
CD11c+CD8α+ DCs are derived from lymphoid-committed 
progenitors (21), it was demonstrated recently that any of the 
IPCs and conventional DCs can be generated via lymphoid 
and myeloid progenitors (22–27). Specifi  cally, all IPCs and 
conventional DCs are generated by mouse CMPs, GMPs, 
CLPs, and pro–T1 cells, whereas IPC and DC diff  erentiation 
potential is lost once defi  nitive MEP or B cell commitment 
occurs (22–27). Thus, in contrast to other hematopoietic lin-
eages, IPC and DC potentials are conserved along lymphoid 
and myeloid developmental pathways.
Flt3 is a receptor tyrosine kinase with homology to c-Kit 
(the receptor for stem cell factor) and c-fms (the receptor for 
M-CSF; reference 28) that has a nonredundant role in steady-
state diff  erentiation of IPCs and DCs in vivo: Flt3 ligand 
(Flt3L)-defi  cient mice and mice with hematopoietic system–
confi  ned deletions of STAT3, a transcription factor activated 
in the Flt3 signaling cascade, as well as mice that are treated 
with fl  t3 tyrosine kinase inhibitors, show massively reduced 
IPCs and DCs (29–31). Conversely, injection or conditional 
expression of Flt3L in mice increases IPCs and DCs, with up 
to 30% of mouse spleen cells expressing CD11c (32–34). 
Furthermore, Flt3L as a single cytokine is capable of inducing 
diff   erentiation of IPCs and DCs in mouse bone marrow 
cell cultures (35).
Flt3 is expressed in mouse short-term HSCs and multi-
potent progenitors (36, 37) in most CLPs and CMPs, at lo-
wer levels on fractions of GMPs and pro–T1 cells, as well as 
on mature steady-state IPCs and DCs. It is down-regulated 
on pro–B cells, further downstream T cell progenitors, and 
absent on MEPs (33, 38). To determine what might de-
fi  ne IPC and DC developmental potential in lymphoid- 
and   myeloid-committed cells, we and others showed that 
in vitro and in vivo IPC, DC, and Langerhans cell diff  er-
entiation potential is confined to Flt3-expressing hema-
topoietic progenitors (33, 38, 39). Furthermore, we de-
  monstrated that injection of Flt3L expands Flt3+ but not 
downstream Flt3− progenitors and drives IPC and DC de-
velopment along both lymphoid and myeloid diff  erentiation 
pathways (33).
Based on these data, we postulate that high environmen-
tal Flt3L levels and consecutive Flt3 signaling might be both 
the earliest event and a continuous regulator that determines 
IPC and DC developmental outcomes in bone marrow he-
matopoietic progenitor cells. Thus, we were interested to test 
whether enforced Flt3 expression and signaling would be suf-
fi  cient to instruct IPC and DC development from Flt3− pro-
genitor cells and enhance IPC and DC development from 
Flt3+ progenitor cells, respectively.
RESULTS
Enforced expression of human Flt3 in Flt3− and Flt3+ 
progenitors rescues and enhances IPC and DC developmental 
potential, respectively
We used a bicistronic retroviral transduction system to trans-
duce human Flt3 into progenitor cells. The constructs carrying 
either GFP or huFlt3-GFP are shown in Fig. S1 A, available at 
http://www.jem.org/cgi/content/full/jem.20051645/DC1. 
Lin−IL-7Rα−Thy1.1−c-Kit+ bone marrow cells that contain 
a heterogeneous fraction of progenitors, including multipotent 
progenitors and myeloid-committed cells, and are devoid of 
Thy1.1+ HSCs, IL-7Rα+ lymphoid–committed cells, and 
mature lineage cells, were sorted into Flt3− (Flt3− progenitors 
also containing Flt3− MEPs) and Flt3+ (Flt3+ progenitors con-
taining multipotent progenitors and Flt3+ CMPs) cell frac-
tions (Fig. 1 A; references 33, 36–38) and consecutively 
retrovirally transfected as described in Materials and methods. 
Fig. S1 B shows typical 18-h coculture transduction effi   cien-
cies (18–26%) in Flt3− and Flt3+ progenitors as determined by 
GFP expression.
To study the eff  ects of enforced huFlt3 expression on IPC 
and DC development, Flt3− and Flt3+ progenitors were trans-
duced with control-GFP or huFlt3-GFP and cultured in hu-
man Flt3L-Ig fusion protein (huFlt3L-Ig)– and stem cell factor 
(SCF)-supplemented media. Cultures were analyzed for cell 
numbers and the presence of IPCs and DCs at days 4, 8, and 12. 
Freshly isolated Flt3− progenitors did not express CD11c or 
MHC class II (not depicted). As expected, unmanipulated 
Flt3− progenitors (not depicted) as well as GFP-transduced 
Flt3− progenitors gave rise to no or very few CD11c+ MHC 
class II+ (up to 1.1%) and CD11c+B220+ (up to 0.5%) cells 
(Fig. 1 B, top). In contrast, huFlt3-GFP–transduced Flt3− 
progenitors diff  erentiated into CD11c+ MHC class II+ and 
CD11c+B220+ cells that increased in re  lative numbers from 
day 4 to 8 of culture (Fig. 1 B, bottom).   Similarly, GFP-trans-
duced as well as huFlt3-transduced Flt3+ progenitor cells gave JEM VOL. 203, January 23, 2006  229
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rise to CD11c+ MHC class II+ and CD11c+B220+ cells, with 
huFlt3-transdced Flt3+ progenitor cells producing slightly 
higher relative numbers of both cell types (Fig. 1 C). To quan-
tify absolute CD11c+ cell   production, cell numbers were de-
termined at days 4, 8, and 12 of culture. Numbers peaked at 
day 8 of culture, with huFlt3-transduced Flt3+ progenitors 
Figure 1.  Enforced expression of human Flt3 in Flt3− and Flt3+ 
progenitors rescues and enhances IPC and DC developmental poten-
tial, respectively. (A) Contour plots indicate sorting gates for mouse 
bone marrow, c-Kit–enriched Flt3−Lin−IL-7Rα−Thy1.1−c-Kit+ (Flt3− pro-
genitors), and Flt3+Lin−IL-7Rα−Thy1.1−c-Kit+ (Flt3+ progenitors) cells. 
(B) Flow cytometric analysis of GFP+ cells derived from control-GFP– and 
huFlt3-GFP–transduced Flt3− progenitors cultured for 4 or 8 d in hu-
Flt3L-Ig– and SCF-supplemented media. (C) Flow cytometric analysis of 
GFP+ cells derived from control-GFP– and huFlt3-GFP–transduced Flt3+ 
progenitors cultured for 4 or 8 d in huFlt3L-Ig– and SCF-supplemented 
  media. (B and C) Numbers at gates represent percentages of total plotted 
cells. Results are from one representative experiment out of six each. 
(D) Graph depicts numbers of cells derived from 105 retrovirus-transduced 
progenitor cells cultured with huFlt3L-Ig and SCF at days 4, 8, and 
12 of culture. ■, GFP-transduced Flt3− progenitors; ●, huFlt3-transduced 
Flt3− progenitors; ◇, GFP-transduced Flt3+ progenitors; △, huFlt3- transduced 
Flt3+ progenitors. Each point represents mean values ± SD from three 
independent experiments. (E) Bars show total IPC (CD11c+B220+) 
and DC (CD11c+B220−) yields per 105 retrovirus-transduced pro  -
genitor cells at day 8. The data represents mean values ± SD from three 
independent experiments. Statistical analysis was performed by 
Student’s t test.230  FLT3 REGULATION OF DC AND IPC DEVELOPMENT | Onai et al.
producing the highest cell numbers ( 14-fold expansion of 
input cells), followed by intermediate expansion (6–9-fold) of 
both GFP-transduced Flt3+ and huFlt3-transduced Flt3− pro-
genitors, and low expansion (3–4-fold) of GFP-transduced 
Flt3− progenitors (Fig. 1 D). The total cellular expansion was 
paralleled by a peak expansion of CD11c+ MHC class II+ and 
CD11c+B220+ cells at day 8 of culture (Fig. 1, B–E). Interest-
ingly, huFlt3-transduced Flt3+ progenitors produced signifi  -
cantly higher total numbers of both CD11c+ MHC class II+ 
and CD11c+B220+ cells compared with GFP-transduced 
Flt3+ progenitors (Fig. 1 E), with somewhat higher relative 
CD11c+B220+ cell numbers (Fig. 1, C and E).
Next, we evaluated IPC- and DC-associated surface 
  antigen expression and function of CD11c+B220+ and 
CD11c+B220− cells derived from diff  erent progenitor cell 
populations at day 8 of culture. Consistent with typical mouse 
IPC and DC phenotypes, CD11c+B220+ cells expressed 
Gr-1, Ly6C, and CD45RA, whereas CD11c+B220− cells ex-
pressed CD11b and intermediate levels of CD80 and CD86, 
respectively (Fig. 2 A). Furthermore, CD11c+B220+ cells 
produced substantial amounts of IFN-α upon stimulation 
with either infl  uenza virus or CpG, whereas CD11c+B220− 
cells did not (Fig. 2 B). CD11c+B220− cells, but not 
CD11c+B220+ cells, displayed typical DC morphology (Fig. 
2 C) and were effi   cient stimulators in allogeneic MLR cul-
tures, as evaluated by thymidine incorporation (Fig. 2 D). 
Therefore, CD11c+B220+ cells phenotypically and function-
ally were typical IPCs, whereas CD11c+B220− cells were 
typical conventional DCs. Collectively, these results indicate 
that huFlt3 signaling rescues and enhances the development 
of functional IPCs and DCs from Flt3− and Flt3+ hemato-
poietic progenitor cell populations, respectively. In addition, 
it suggests that strong Flt3 signaling slightly skews develop-
ment toward an IPC phenotype.
Enforced expression of huFlt3 is suffi  cient to rescue IPC 
and DC development from MEPs and enhances IPC and DC 
development from GMPs
In normal mouse and human hematopoiesis, IPC and DC 
developmental potentials are maintained from Flt3+ CMPs 
to downstream Flt3+ GMPs, but are lost in Flt3− MEPs 
(23–27, 33, 38). Thus, we tested whether enforced huFlt3 
expression in MEPs would be suffi   cient to rescue IPC and 
DC development. As comparator cell population, we used 
huFlt3-transduced GMPs and GFP-transduced CMPs (GFP+-
CMPs). As reported previously for unmanipulated MEPs, 
GFP-transduced MEPs (GFP+-MEPs) gave rise to no or 
very few CD11c+ cells (Fig. 3 A, top). In contrast, huFlt3+-
MEPs gave rise to CD11c+B220+ cells and CD11c+B220− 
cells at day 8 in huFlt3L-Ig– and SCF-supplemented cul-
tures, at least as effi   cient as GFP+-GMPs (Fig. 3, A–C). 
Similarly as from huFlt3-transduced Flt3+ progenitor cells, 
CD11c+B220+ and CD11c+B220− cell development was 
signifi  cantly enhanced from huFlt3-transduced GMPs (Fig. 3, 
B and C). Upon infl   uenza virus or CpG stimulation, 
  huFlt3+-MEP– and huFlt3+-GMP–derived CD11c+B220+ 
cells produced IFN-α (Fig. 3 D), suggesting that these cells 
are functional.
As reported previously for untransduced CMPs (22–27, 38), 
GFP+-CMPs generated both IPCs and DCs. The effi   cacy 
of GFP+-CMPs to produce these off  spring cells was about 
threefold higher than that observed from huFlt3+-GMPs 
(Fig. 3 C). Thus, enforced huFlt3 expression is suffi   cient to 
rescue IPC and DC developmental potential in MEPs to   levels 
comparable to their developmental counterparts, GFP+-GMPs. 
Furthermore, huFlt3 expression enhances IPC and DC develop-
ment from GMPs, but not to levels observed in the upstream 
CMP population.
Enforced expression of huFlt3 permits myelomonocytic 
development from huFlt3+-MEPs but not megakaryocyte/
erythrocyte development from huFlt3+-GMPs
Because huFlt3 signaling in MEPs activated IPC and DC 
  development, a diff  erentiation option normally confi  ned to 
Flt3+ progenitors as CMPs and GMPs, we were interested to 
test whether huFlt3 signaling in MEPs would also reestablish 
myeloid CFU activity. GFP+-transduced CMPs, GMPs, and 
MEPs gave rise to their respective colony types, but with some-
what lower plating effi   cacy as compared with freshly isolated 
CMPs, GMPs, and MEPs (Fig. 4 A; reference 2). huFlt3+-
MEPs gave rise to not only erythroid-affi   liated colonies but 
also granulocyte/macrophage (GM)-affi   liated colonies, in-
cluding CFU-G, CFU-M, and CFU-GM (Fig. 4 A). Com-
pared with CMPs and GMPs, the myelomonocytic colony–
forming effi   ciency of huFlt3+-MEPs was lower; however, 
the diversity of colony formation resembled that of CMPs 
with the exception that no CFU-Mix colonies developed. 
No substantial diff  erence in CFU activity was observed in 
huFlt3+-GMPs compared with GFP+-GMPs (Fig. 4 A). 
Thus, huFlt3 signaling in MEPs reestablishes myelomono-
cytic CFU activity, whereas huFlt3 signaling in GMPs does 
not aff  ect their overall CFU activity and particularly does not 
reestablish megakaryocyte/erythrocyte read out.
Enforced expression of huFlt3 in MEPs is suffi  cient to rescue 
IPC, DC, and myelomonocytic cell development in vivo
To test the robustness of Flt3 transduction–mediated eff  ects 
observed in vitro, we compared in vivo reconstitution activ-
ity of GFP+-MEPs, huFlt3+-MEPs, and GFP+-CMPs. 2 × 
104 cells of each progenitor population combined with 2 × 
105 cells of host bone marrow cells were transplanted into le-
thally irradiated mice, and spleen progeny cells were analyzed 
on day 7. As reported previously for MEPs, GFP+-MEPs 
produced  0.7% of nucleated GFP+ spleen cells that con-
sisted mostly of Ter119+ erythroid cells, but no DCs, IPCs, 
or Gr-1+ myeloid cells (Fig. 4 B, top; references 2, 23, and 25). 
In contrast, huFlt3+-MEPs gave rise to  2.7% of nucleated 
GFP+ spleen cells containing CD11c+ MHC class II+ con-
ventional DCs, low numbers of CD11c+B220+ IPCs, as well 
as Ter119+ erythroid and Gr-1+ myeloid cells (Fig. 4 B, middle). 
As expected, GFP+-CMPs gave rise to  6.0% of nucleated 
GFP+ spleen cells that contained DCs, IPCs, as well as JEM VOL. 203, January 23, 2006  231
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  erythroid and myeloid cells (Fig. 4 B, bottom; references 2, 
23, and 25). This formally demonstrates that enforced expres-
sion of huFlt3 is suffi   cient to rescue in vivo IPC, DC, and 
myelomonocytic cell development from MEPs.
HuFlt3 signaling in MEPs induces activation of DC and 
myeloid development–associated genes
To evaluate the immediate consequences of huFlt3 signaling 
on gene transcription profi  les that might be involved in the 
consecutive activation of IPC, DC, and myelomonocytic de-
velopmental options, we analyzed the transcription of a panel 
of IPC, DC, and myeloid development–associated genes by 
RT-PCR in huFlt3+-MEPs. STAT3, an indispensable tran-
scription factor for Flt3L-mediated DC development (30), 
was hardly detectable in GFP+-MEPs but was clearly up-
regulated in huFlt3+-MEPs. Furthermore, huFlt3+-MEPs 
but not GFP+-MEPs expressed myelomonocytic develop-
ment–associated genes, such as the cytokine receptors for 
G-CSF, M-CSF, and GM-CSF, as well as the transcription 
factors C/EBPα and PU.1, similar to that found in GFP+-
GMPs, huFlt3+-GMPs, and normal CMPs (Fig. 5 A; refer-
ences 2 and 40). However, transcription factors RelB, ICSBP, 
and Id2 could not be detected in any of the retrovirus-trans-
duced MEPs and GMPs, whereas they were detectable in 
unmanipulated CMPs (Fig. 5 A). Real-time RT-PCR re-
vealed low-level STAT3 expression in GFP+-MEPs and 
similar high levels of STAT3 expression in huFlt3+-MEPs, 
GFP+-GMPs, huFlt3+-GMPs, and CMPs (Fig. 5 B). Fur-
thermore, PU.1 expression levels in huFlt3+-MEPs increased 
to levels found in CMPs, whereas expression levels of this 
gene were somewhat higher in GM-committed GFP+-
GMPs and huFlt3+-GMPs (Fig. 5 B).
Figure 2.  IPCs and DCs developed in culture from huFlt3-
  transduced Flt3− progenitors are functional. (A) Contour plots indi-
cate surface markers (closed histogram) and respective isotype controls 
(open histogram) on CD11c+B220+ and CD11c+B220− cells derived from 
huFlt3L-Ig– and SCF-cultured huFlt3-transduced Flt3− progenitors. 
CD11c+B220+ and CD11c+B220− cells show typical phenotypes of IPCs 
and DCs, respectively. Results are from one representative experiment out 
of three. (B) Sorted CD11c+B220+ IPCs but not CD11c+B220− DCs, both 
derived from either huFlt3-transduced Flt3− progenitors or GFP-
transduced Flt3+ progenitors, produce IFN-α upon infl  uenza virus or 
CpG stimulation. Culture supernatants were collected after 24 h and ana-
lyzed by ELISA. Results are from one representative experiment out of three. 
(C) About half of day 8 progeny from huFlt3-transduced Flt3− progenitors 
display typical DC morphology. Giemsa-stained cytospin, photographed at 
a magnifi  cation of 40. (D) In vitro–generated CD11c+B220− cells from 
retrovirus-transduced progenitors are effi  cient stimulators of allogeneic 
T cells. Graph depicts thymidine incorporation of 2 × 105 allogeneic 
BALB/c spleen CD4+ T cells incubated with graded numbers (x axis) of 
sorted CD11c+B220− DCs derived from huFlt3-transduced Flt3− progeni-
tors (●), CD11c+B220+ IPCs derived from huFlt3-transduced Flt3− pro-
genitors (■), or CD11c+B220− DCs derived from GFP-transduced Flt3+ 
progenitors (△), and CD11c+B220+ IPCs derived from GFP-transduced 
Flt3+ progenitors (◇). Results are from one representative experiment 
out of three.232  FLT3 REGULATION OF DC AND IPC DEVELOPMENT | Onai et al.
Consistent with their maintained Meg/E-developmental po-
tential, Meg/E-related genes, such as EpoR, β-globin, GATA-1, 
and GATA-2, were still transcribed in huFlt3+-MEPs, although 
the expression of NF-E2 decreased (Fig. 5 A). Interestingly, 
huFlt3+-GMP showed some transcription of Meg/E develop-
ment–associated genes as β-globin and GATA-1. However, 
GATA-2 and NF-E2 transcripts were not detectable, and hu-
Flt3+-GMPs were not able to give rise to Meg/E lineage col-
onies (Figs. 4 A and 5 A). Collectively, these results demonstrate 
on a molecular level that MEPs have a latent IPC, DC, 
and myelomonocytic lineage potential that is inducible by 
enforced Flt3 signaling.
HuFlt3 signaling in MEPs leads to downstream 
STAT3 phosphorylation
To test activation of STAT3 in huFlt3+-MEPs, we per-
formed intracellular phospho-STAT3 staining in retrovirus-
transduced MEPs that were Flt3L deprived and then 
stimulated with huFlt3L-Ig. Indeed, phosphorylation of 
STAT3 was detected in huFlt3+-MEPs but not in GFP+-
MEPs, indicating that as expected (30) STAT3 is a down-
stream activated transcription factor of enforced huFlt3 
signaling (Fig. 6 A).
Enforced STAT3 or PU.1 expression instructs MEPs 
to differentiate into IPCs, DCs, and GM lineage cells
Given the importance of STAT3 for IPC and DC devel-
opment, and the fi  nding that STAT3 and PU.1 were up-
regulated in huFlt3+-MEPs, we tested whether STAT3 and 
PU.1 could directly activate IPC, DC, and myelomonocytic 
development from MEPs. Mouse STAT3 and PU.1 were 
transduced into MEPs using retrovirus expression vectors, 
respectively (Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20051645/DC1). However, survival of cells 
was low when cultured in SCF alone or SCF and huFlt3L-
Ig (not depicted). To possibly support the survival of MEPs, 
we fi  rst added thrombopoietin (TPO), followed by TPO and 
huFlt3L-Ig to SCF in consecutive   cultures. STAT3+-MEPs 
Figure 3.  Enforced expression of huFlt3 is suffi  cient to rescue IPC 
and DC development from MEPs and enhances IPC and DC develop-
ment from GMPs. (A and B) Flow cytometric analysis of GFP+ cells from 
control-GFP– and huFlt3-transduced MEPs (A) and GMPs (B). Retrovirus-
transduced cells were cultured for 4 or 8 d in huFlt3L-Ig– and SCF-
  supplemented media. Numbers at gates represent percentages of total 
plotted cells. Results are from one representative experiment out of three. 
(C) Bars show total IPC (CD11c+B220+) and DC (CD11c+B220−) yields per 
5 × 104 retrovirus-transduced MEPs, GMPs, and CMPs at day 8. The data 
represents mean values ± SD from three independent experiments. 
  Statistical analysis was performed by Student’s t test. (D) IPCs developed 
from huFlt3+-MEPs and huFlt3+-GMPs are functional. Bar graph shows 
IFN-α production by sorted CD11c+B220+ cells derived from day 8 culture 
of huFlt3+-MEPs or huFlt3+-GMPs stimulated with infl  uenza virus or CpG. 
Culture supernatants were collected after 24 h and analyzed by ELISA. 
Results are from one representative experiment out of three.JEM VOL. 203, January 23, 2006  233
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and PU.1+-MEPs diff  erentiated into CD11c+B220+ and 
CD11c+B220− cells at day 8 in both SCF as well as TPO 
(not depicted) and, with even higher effi   cacy in SCF, TPO, 
and huFlt3L-Ig, supplemented cultures (Fig. 6 B). Inter-
estingly, enforced expression of STAT3 or PU.1 in MEPs 
in turn led to the up-regulation of mouse Flt3 mRNA 
levels (Fig. S3, available at http://www.jem.org/cgi/content/
full/jem.20051645/DC1).
To test myeloid CFU activity of these cells, STAT3+-
MEPs and PU.1+-MEPs were plated in methylcellulose assays. 
Both STAT3+-MEPs and PU.1+-MEPs gave rise to CFU-G, 
CFU-M, and CFU-GM colonies, but not to Meg/E-affi   liated 
colonies (Fig. 6 C).
Finally, we evaluated the expression of GATA-1, a non-
redundant transcription factor, for megakaryocyte/erythro-
cyte development by real-time RT-PCR. GATA-1 expression 
was down-regulated in STAT3+-MEPs and PU.1+-MEPs 
compared with that in GFP+-MEPs,  huFlt3+-MEPs, and 
CMPs (Fig. 6 D). Thus, enforced expression of STAT3 and 
PU.1 in MEPs reprogrammed them to diff  erentiate into IPCs, 
DCs, and myelomonocytic cell lineages and inhibited Meg/E 
lineage potentials, indicating that strong Flt3 downstream sig-
nals were capable of inducing complete lineage conversion.
DISCUSSION
A standing question in early hematopoiesis is whether cyto-
kine signaling is suffi   cient to induce cell fate decisions. Here, 
we showed that enforced expression of huFlt3 in Flt3− pro-
genitors rescued their potential to diff  erentiate into functional 
IPCs and DCs with comparable in vitro diff  erentiation effi   -
ciency as Flt3+ progenitors (Figs. 1 and 2). We also demon-
strated that enforced expression of huFlt3 in MEPs, which 
under normal conditions cannot give rise to IPCs and DCs 
(23–27) and are contained in Flt3− progenitor cells, induced 
Figure 4.  Enforced expression of huFlt3 permits myelomono-
cytic development from huFlt3+-MEPs but not megakaryocyte/
erythrocyte development from huFlt3+-GMPs. (A) Bar graph shows 
myeloid colony–forming activity in normal and retrovirus-transduced 
myeloid progenitors (MEPs, GMPs, and CMPs). CFU-GEMM, CFU-
granulocyte/ erythroid/macrophage/megakaryocyte;  CFU-MegE,  CFU-
megakaryocyte/erythroid; CFU-Meg, CFU-megakaryocyte; BFU-E, 
burst-forming units/erythroid; CFU-GM, CFU-granulocyte/macrophage; 
CFU-M, CFU-macrophage; CFU-G, CFU-granulocyte. Results are from 
one representative experiment out of three. 200 GFP+ cells were plated 
each. (B) Enforced expression of huFlt3 in MEPs is suffi  cient to rescue 
IPC, DC, and myelomonocytic cell development in vivo. Contour plots 
show GFP expression in day 7 spleen progeny of GFP+-MEPs, huFlt3+-
MEPs, and GFP+-CMPs. Numbers at gates represent percentages of 
total plotted cells. Results are from one representative experiment 
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in vitro IPC and DC diff  erentiation comparable to that ob-
served from GFP+-GMPs (Fig. 3). Furthermore, huFlt3+-
MEPs diff  erentiated into IPCs and DCs upon in vivo transfer, 
the most informative assay available to prove the robustness 
of in vitro observations (Fig. 4 B). Thus, these data demon-
strate that enforced expression and signaling of huFlt3 in 
Flt3− progenitors deliver an instructive signal to activate la-
tent IPC and DC diff  erentiation programs.
Overexpression of huFlt3 in total Flt3+ progenitors, in 
Flt3-expressing GMPs, and in CLPs (of which  70% are 
Flt3+) led to a gain of higher relative and absolute (two- to 
threefold) numbers of IPCs and DCs in vitro (Figs. 1, D and E, 
and 3 C, and not depicted). Thus, beyond activation, increased 
Flt3 signaling also enhanced IPC and DC   development. The 
gain in off  spring cells was consistently higher for IPCs than for 
DCs (Figs. 1 E and 3 C), in line with our previous fi  ndings 
that after 10 d of in vivo Flt3L injection, spleen IPCs and DCs 
were expanded on average 28- and 21-fold, respectively (33). 
This suggests that a continuous strong Flt3 signal might induce 
a shift toward relatively higher IPC levels.
We previously found that Flt3 is expressed in lymphoid- 
and myeloid-committed progenitor cells, and in vivo Flt3L 
application mediates the expansion of both cell types with-
out changing their biology (33). The enforced expression of 
huFlt3 in MEPs not only led to a gain of IPC and DC devel-
opmental capacity, but, with the exception of mixed colony 
formation, also to a gain of CFU activity of upstream my-
eloid progenitors as well as to diff  erentiation of erythroid 
and myelomonocytic cells in vivo (Fig. 4 A). In contrast, 
huFlt3 signaling in GMPs did not activate megakaryocyte/
erythrocyte potential (Fig. 4 A). This implies that beyond 
activation and enhancement of IPC and DC development, 
Figure 5.  HuFlt3 signaling in MEPs induces activation of DC and 
myeloid development–associated genes. (A) RT-PCR analysis of mye-
loid lineage differentiation–affi  liated genes, including cytokine recep-
tors and transcription factors in retrovirus-transduced myeloid 
progenitors. The PCR products were electrophoresed on agarose gel 
and visualized with ethidium bromide. Results are from one represen-
tative experiment out of three. (B) Expression levels of STAT3 and 
PU.1 mRNA were assessed by real-time RT-PCR. Data were normalized 
by the level of 18s rRNA expression in each sample. (A and B) cDNA 
products equivalent to RNAs from 200 progenitors were   analyzed. 
Results are from one representative experiment out of three.JEM VOL. 203, January 23, 2006  235
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Flt3 signaling is not immediately deterministic but primarily 
opens access to an IPC, DC, and myelomonocytic diff  er-
entiation program. Thus, we propose that fi  nal IPC and DC 
lineage outcome might be a gradual process, depending on 
continuous strong Flt3 signaling.
What are the Flt3 signaling–initiated downstream molec-
ular events? It was shown that hematopoietic system–confi  ned 
deletion of STAT3 transcription factor leads to the inhibition 
of Flt3-driven IPC and DC development (30). Furthermore, 
human Flt3 transfection and stimulation with Flt3L in mouse 
myeloid 32Dcl3 cells leads to the induction of PU.1 and 
C/EBPα expression (41). These transcription factors are in-
dispensable for granulocyte and monocyte development (42), 
and it was shown that PU.1 cooperatively with C/EBPα ac-
tivates myeloid development–associated cytokine receptor 
genes, including G-CSFR, M-CSFR, and GM-CSFR (42). 
Interestingly, PU.1-defi  cient mice, in addition to other he-
matopoietic defects, lack either CD8α− or both CD8α− and 
CD8α+ DCs, depending on the type of PU.1 deletion (43, 44). 
Here, we showed that enforced   huFlt3 signaling in MEPs re-
sults in enhanced expression of IPC, DC, and GM lineage 
development related transcription factors STAT3, PU.1, and 
C/EBPα, as well as expression of G-, M-, and GM-CSF cyto-
kine receptors (Fig. 5). Thus, at least in terms of these RNA 
transcripts, huFlt3+-MEPs but not GFP+-MEPs resembled 
the gene expression profi  les of CMPs (2, 40).
Importantly, enforced expression of STAT3 or PU.1 in 
Flt3− MEPs was again suffi   cient to permit the development 
of both IPCs and DCs (Fig. 6 B). This, however, was only 
possible once TPO was added to SCF or SCF and Flt3L in 
cultures. Thus, TPO possibly substitutes for a survival signal 
otherwise delivered by Flt3. In addition, or alternatively, 
TPO might be involved in the phosphorylation of over-
expressed STAT3 (45). Interestingly, enforced expression of 
STAT3 or PU.1 in MEPs led to the up-regulation of mouse 
Flt3 mRNA levels (Fig. S3). This in turn likely allowed cul-
ture-supplemented human Flt3L to cross-reactively stimulate 
STAT3- or PU.1-transduced cells via mouse Flt3. These re-
sults suggest a self-sustaining eff  ect of Flt3 signaling–induced 
Flt3 transcription via downstream STAT3 and PU.1.
As enforced expression of huFlt3 in MEPs did not termi-
nate megakaryocyte/erythrocyte diff  erentiation  potential, 
Figure 6.  HuFlt3 signaling in MEPs leads to downstream STAT3 
phosphorylation; enforced STAT3 or PU.1 expression instructs 
MEPs to differentiate into IPCs, DCs, and GM lineage cells and 
suppresses GATA-1 expression. (A) Contour plots show phosho-
STAT3 expression (closed histogram) and respective isotype controls 
(open histogram) in cytokine-deprived and consecutively 5- and 
15-min huFlt3L-Ig–stimulated huFlt3+-MEPs by intracellular staining. 
Results are from one representative experiment out of three. (B) Flow 
cytometric analysis of STAT3+-MEPs and PU.1+-MEPs cultured for 8 d 
in huFlt3L-Ig–, SCF-, and TPO-supplemented media. Results are from 
one representative experiment out of three. (C) Bar graph shows mye-
loid colony–forming activity in GFP+-MEPs, STAT3+-MEPs, and 
PU.1+-MEPs. Results are from one representative experiment out of 
three. (D) Expression of GATA-1 mRNA was assessed by real-time 
RT-PCR. Data were normalized by the level of 18s rRNA expression in 
each   sample. cDNA products equivalent to RNAs from 200 progenitors 
were   analyzed. Results are from one representative experiment 
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whereas huFlt3 expression in GMPs did not lead to a gain of 
these diff  erentiation potentials (Fig. 4 A), how can Flt3 sig-
naling be integrated in megakaryocyte/erythrocyte versus 
IPC, DC, and GM lineage commitment? By using PU.1gfp 
reporter mice, PU.1 expression was recently mapped in 
early hematopoietic progenitor cells (46). It was shown that 
PU.1+Flt3+ CMPs contain high myelomonocytic develop-
mental potential, whereas PU.1−Flt3− CMPs and PU.1− 
MEPs have high megakaryocyte/erythrocyte potential (46). 
The data presented here suggests that Flt3 might be critical in 
PU.1 regulation, although this likely will not be an exclusive 
event. GATA-1 is a nonredundant transcription factor for 
megakaryocyte and erythrocyte development (47). DNA 
binding activity of GATA-1 can be suppressed by enforced 
PU.1 expression, resulting in a diff  erentiation block and 
apoptotic cell death of an erythroid cell line (48). Conversely, 
GATA-1 inhibits the binding of PU.1 to c-Jun, a critical co-
activator of myeloid gene transactivation by PU.1 (49). Fur-
thermore, GATA-1 interferes with DNA binding activity of 
STAT3 and inhibits TPO-dependent growth of the Ba/F3 
cell line (50). Thus, as suggested previously for PU.1 and 
GATA-1 (51, 52), relative dosage of gene transcription and 
protein levels will likely determine lineage outcomes. Indeed, 
STAT3 and PU.1 expression levels in huFlt3+-MEPs were 
increased to levels of normal CMPs and were somewhat 
lower than those observed in GFP+-GMPs or huFlt3+-
GMPs (Fig. 5). Thus, it is possible that MEPs with relatively 
lower huFlt3 and consecutive STAT3 and PU.1 expression 
do not fully inhibit GATA-1, whereas high Flt3 expressing 
and signaling cells develop to IPC, DC, or GM lineages. 
Of note, enforced expression of STAT3 and PU.1 in MEPs 
suppressed  GATA-1 expression and inhibited megakaryo-
cyte/erythrocyte development (Fig. 6, C and D). HuFlt3 
overexpression in GMPs in turn induced some EpoR, β-globin, 
and GATA-1 mRNA expression; however, this was not suf-
fi  cient to reactivate megakaryocyte/erythrocyte development 
as demonstrated for enforced high-level GATA-1 expression 
in GMPs (Figs. 4 A and 5 A; reference 13).
Because overexpression of huFlt3 in Flt3− progenitors 
does not occur under physiologic conditions, what do these 
fi  ndings imply for normal hematopoiesis? Flt3 is expressed on 
short-term HSCs, multipotent progenitors, CLPs, CMPs, and 
GMPs, and in vivo injection of Flt3L resulted in increased 
numbers of these cells as well as IPCs and DCs, whereas 
MEPs and their progeny remained unchanged (32, 33). The 
data presented here demonstrate that enforced Flt3 cytokine 
receptor signaling is suffi   cient to activate as well as enhance 
IPC and DC diff   erentiation programs, suggesting that in-
structive cytokine signaling might indeed occur in hemato-
poiesis. Thus, we speculate that once Flt3+ short-term HSCs 
and their off  spring Flt3+ cells are exposed to Flt3L-rich envi-
ronments, these cells will be instructed to diff  erentiate into 
IPCs and DCs. This might be enhanced by a self-  sustaining 
process in which Flt3 downstream transcription factors 
STAT3 and PU.1 in turn maintain Flt3 receptor expression. 
However, Flt3 signaling does not immediately silence other 
developmental options. It is likely that most Flt3-expressing 
progenitors will not continuously be stimulated via Flt3L but 
will receive and activate alternative signals, and thus consecu-
tively acquire myeloid or lymphoid, but not IPC or DC, cell 
fates. Beyond previous studies, our data further emphasize 
that IPC and DC development does not fi  t into a deterministic 
“lymphoid” nor “myeloid” lineage, but rather a “Flt3-per-
missive” developmental model, where Flt3-expressing pro-
genitors maintain IPC and DC diff  erentiation  options  in 
response to Flt3L as long as no competing signal shuts these 
down. It will be of interest to test whether downstream divid-
ing Flt3+ common IPC and DC progenitors with silenced 
  alternative developmental programs exist and which critical 
factors are involved in fi  nal IPC or DC lineage termination.
MATERIALS AND METHODS
Mice. C57BL/6 (CD45.2), C57BL/Ka-Thy1.1 (CD45.1), and BALB/c 
mice (Charles River Laboratories) were maintained at the Institute for Re-
search in Biomedicine animal facility in accordance with the Swiss Federal 
Veterinary Offi   ce guidelines.
Flow cytometry and cell sorting. Hematopoietic progenitors were iso-
lated as described previously with minor modifi  cations (2, 37). Bone marrow 
cells were immunomagnetically preenriched for c-Kit+ cells using APC-con-
jugated c-Kit antibodies (2B8; eBioscience) and APC microbeads (Miltenyi 
Biotec). Cells were then stained with monoclonal antibodies as indicated 
below. Flt3+ and Flt3− hematopoietic progenitors were sorted as lineage− 
(CD3ε, 145-2C11; CD4, GK1.5; CD8, 53-6.7; B220, RA3-6B2; CD19, 
MB19-1; CD11b, M1/70; Gr-1, RB6-8C5; and TER119, TER119), IL-
7Rα− (A7R34), Thy1.1− (19XE5), c-Kit+, and Flt3+or− (A2F10.1) cells. 
Thus, Flt3+ and Flt3− hematopoietic progenitors did not contain Thy1.1+ 
HSCs or IL-7Rα+ lymphoid progenitors. Myeloid progenitors were sorted 
as Lin−Sca-1− (E13-161-7) c-Kit+CD34+ (RAM34) FcγRlo (2.5G2; 
CMPs), Lin−Sca-1+c-Kit+CD34+FcγRhigh (GMPs), and Lin−Sca-1−c-
Kit+CD34−FcγRlo (MEPs) cells. For IPC and DC analysis and sorting, ad-
ditional monoclonal antibodies against the following antigens were used: 
CD11c (N418), MHC class II (I-A/I-E; M15/114.15.2), Ly6C (AL-21), 
CD45RA (A20.1.7), CD80 (16-10A1), and CD86 (GL-1). Cells were sorted 
and analyzed using a FACSCalibur and FACSAria (Becton Dickinson).
Retroviral transduction of hematopoietic progenitors. The full length 
of human Flt3, mouse STAT3, and PU.1 cDNA was inserted into a retro-
viral expression vector, pMYs-IRES-GFP, respectively (53). These constructs 
were transiently transfected into Phoenix-Ampho cells by LipofectAMINE 
(Invitrogen). The amphotropic retrovirus supernatants were used to trans-
duce GP+E-86 cells. After 2 d, the brightest GFP-expressing GP+E-86 
cells were FACS sorted and expanded. For transduction of hematopoietic 
progenitor cells, GP+E-86 cells were 20-Gy irradiated and plated in 24-well 
plates at 1.5 × 105 cells per well for 24 h. Progenitor cells were transduced 
by coculture with GP+E-86 for 18 h in IMDM (Invitrogen) containing 2% 
FCS, 4 μg/ml polybrene (Sigma-Aldrich), 100 ng/ml human Flt3L-Ig 
  fusion protein (huFlt3L-Ig), 10 ng/ml mSCF (R&D Systems), and 10 ng/ml 
mIL-11 (R&D Systems). Transduced cells were removed by gentle pipetting 
and then subjected to further assays.
In vitro IPC and DC diff  erentiation  assays. Retrovirus-transduced 
Flt3+ and Flt3− progenitors as well as CMPs, GMPs, and MEPs were cul-
tured in IMDM, supplemented with 10% FCS, 10−4 M 2-ME, sodium py-
ruvate, and antibiotics, 100 ng/ml huFlt3L-Ig, and 10 ng/ml mSCF as 
indicated. Half of the media was replaced every 3 d and new cytokines were 
added. Human Flt3L-Ig fusion protein was produced in Drosophila cells as 
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In vitro myeloid colony formation assays. For myeloid colony–forming 
assays, GFP+-CMPs, GFP+-GMPs, and GFP+-MEPs were sorted after viral 
transduction and were cultured in IMDM-based methylcellulose media (Metho-
cult H4100; StemCell Technologies Inc.), containing 30% FCS, 1% bovine 
  serum albumin, 2 mM l-glutamine, and 50 μM 2-ME, 10 ng/ml mSCF, 
10 ng/ml mIL-3 (R&D Systems), 10 ng/ml mIL-11, 10 ng/ml mGM-CSF 
(R&D Systems), 10 ng/ml mTpo (R&D Systems), 1 U/ml hEpo (Roche), and 
100 ng/ml huFlt3L-Ig. Colonies were determined and enumerated under an 
inverted microscope consecutively from day 3 to 8. In some cases, to confi  rm 
colony types, colonies were picked using fi  ne-drawn pasteur pipettes, spun on 
slides, Giemsa stained, and evaluated by light microscopy.
In vivo reconstitution assays. 2 × 104 CD45.2 GFP+-MEPs, huFlt3+-
MEPs, or GFP+-CMPs each were injected intravenously into lethally irradi-
ated (2 × 6 Gy in a 4-h interval from a Cesium 137 source; Biobeam 8000; 
STS GmbH) congenic mice (CD45.1) with 2 × 105 recipient-type CD45.1 
whole bone marrow cells. Mice were killed on day 7. The progeny of 
  donor-derived cells were isolated as described previously (33) and evaluated 
by FACS analysis.
MLR. Graded numbers of sorted, irradiated (25 Gy) IPCs or DCs were 
plated in U-bottom 96-well plates with 2 × 105 immunomagnetically se-
lected (CD4 microbeads; Miltenyi Biotec) BALB/c spleen CD4+ T cells in a 
fi  nal volume of 200 μl RPMI 1640 supplemented with 10% FCS. Cells were 
cultured for 5 d and pulsed with 1 μCi [3H]thymidine (Amersham Biosciences) 
per well during the last 16 h of culture. [3H]thymidine incorporation was 
measured on a β-plate counter (MicroBeta TriLux; EG&G WALLAC).
IFN-𝗂 production. To evaluate IFN-α production, sorted CD11c+B220+ 
IPCs or conventional CD11c+B220− DCs derived from retrovirus-transduced 
progenitors were cultured for 24 h at 105 cells/200 μl in U-bottom 96-well 
plates in RPMI 1640 supplemented with 10% FCS, 2-ME, penicillin G, and 
streptomycin. Either 40 HAU/ml infl  uenza virus (strain A/Beijing/353/89; 
provided by I. Julkunen, National Public Health Institute, Helsinki, Finland) 
or 1 μM CpG-A-ODN (ggT  G  C  A  T  C  G  A  T  G  C  A  gggggG; lowercase letters 
indicate base with phosphorothioate-modifi  ed backbones) was added at start 
of culture and again at 12 h. Culture supernatants were assayed using an 
IFN-α ELISA kit (Performance Biomedical Laboratories).
RT-PCR analysis. Total RNA was extracted from sorted progenitors as 
indicated using TRIzol reagent (Invitrogen) followed by DNase I (Invitro-
gen) treatment. The cDNA was synthesized using random hexamers as well 
as SuperScript II reverse transcriptase (Invitrogen) and amplifi  ed using spe-
cifi  c primers as described previously (13). For real-time PCR, cDNA pro-
ducts equivalent to RNAs from 200 progenitors were amplifi  ed using an 
Applied Biosystems 7900HT Fast Real-Time PCR System. The data were 
normalized by the level of 18s rRNA expression in each sample. Taqman 
probes for mouse STAT3, PU.1, GATA-1, Flt3, and 18s rRNA were pur-
chased from Applied Biosystems.
Intracellular phosoho-STAT3 staining. Retroviral-transduced MEPs 
were cytokine starved for 24 h in 1% FCS-IMDM. Cells were then incu-
bated with or without 100 ng/ml huFlt3L-Ig and analyzed at indicated times 
for phosho-STAT3 by FACS according to the manufacturer’s instructions 
(Cell Signaling).
Statistical analysis. Results of experiments are reported as mean ± SD. 
Diff  erences were analyzed using Student’s t test.
Online supplemental material. Fig. S1 shows the diagrams of pMY-
IRES-GFP and pMY-huFlt3-IRES-GFP bicistronic retroviral expression 
vector constructs and virus transduction effi   cacy in progenitor cells. Fig. S2 
shows the diagrams of pMY-mSTAT3-IRES-GFP and pMY-mPU.1-IRES-
GFP bicistronic retroviral expression vector constructs. Fig. S3 shows the 
analysis of mouse Flt3 mRNA expression in GFP-, huFlt3-, STAT3-, and 
PU.1-transduced MEPs, as well as CMPs. Figs. S1–S3 are available at http://
www.jem.org/cgi/content/full/jem.20051645/DC1.
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